Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Home Page: www.agios.com
88 Sidney Street
Cambridge,
MA
02139
United States
Phone:
617 649 8600
Officers
| Name | Title |
|---|---|
| Mr. Brian M. Goff M.B.A. | CEO & Director |
| Ms. Cecilia Jones | Chief Financial Officer |
| Mr. James William Burns | Corporate Secretary & Chief Legal Officer |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
| Ms. Tsveta Milanova | Chief Commercial Officer |
| Dr. Lewis Clayton Cantley Ph.D. | Founder |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Founder |
| Dr. Craig B. Thompson M.D. | Founder |
| Dr. Shin-San Su Ph.D. | Founder |
| Mr. T. J. Washburn | VP, Controller & Principal Accounting Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 2.4869 |
|---|---|
| Trailing PE: | 4.9909 |
| Price-to-Book MRQ: | 2.0411 |
| Price-to-Sales TTM: | 97.3276 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 383 |